128 related articles for article (PubMed ID: 37926515)
1. Molecular design and systematic optimization of a halogen-bonding system between the asthma interleukin-5 receptor and its cyclic peptide ligand.
He Q; Xu S; Ma X; Zhou Y; Feng W; Lu X; Yu M; Chen Z
Chem Biol Drug Des; 2024 Jan; 103(1):e14387. PubMed ID: 37926515
[TBL] [Abstract][Full Text] [Related]
2. Cyclic peptide interleukin 5 antagonists mimic CD turn recognition epitope for receptor alpha.
Ruchala P; Varadi G; Ishino T; Scibek J; Bhattacharya M; Urbina C; Ryk DV; Uings I; Chaiken I
Biopolymers; 2004 Apr; 73(5):556-68. PubMed ID: 15048779
[TBL] [Abstract][Full Text] [Related]
3. Structure-based improvement of the binding affinity and recognition specificity of peptide competitors to target pediatric IL-5R/IL-5 interaction by gluing halogen bonds at their complex interface.
Chu P; Sheng Y; Shen C; Xia Y; Kong L; Sun J
J Mol Recognit; 2024 Mar; 37(2):e3070. PubMed ID: 37990248
[TBL] [Abstract][Full Text] [Related]
4. Structural Basis of Interleukin-5 Inhibition by the Small Cyclic Peptide AF17121.
Scheide-Noeth JP; Rosen M; Baumstark D; Dietz H; Mueller TD
J Mol Biol; 2019 Feb; 431(4):714-731. PubMed ID: 30529748
[TBL] [Abstract][Full Text] [Related]
5. Molecular design and validation of halogen bonding orthogonal to hydrogen bonding in breast cancer MDM2-peptide complex.
Huang A; Zhou L; Zhang D; Yao J; Zhang Y
J Mol Graph Model; 2016 Nov; 70():40-44. PubMed ID: 27649550
[TBL] [Abstract][Full Text] [Related]
6. Peptide selectivity between the PDZ domains of human pregnancy-related serine proteases (HtrA1, HtrA2, HtrA3, and HtrA4) can be reshaped by different halogen probes.
Sun ML; Sun LM; Wang YQ
J Mol Recognit; 2018 Jun; 31(6):e2698. PubMed ID: 29266444
[TBL] [Abstract][Full Text] [Related]
7. Receptor epitope usage by an interleukin-5 mimetic peptide.
Ishino T; Urbina C; Bhattacharya M; Panarello D; Chaiken I
J Biol Chem; 2005 Jun; 280(24):22951-61. PubMed ID: 15826943
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-5 receptor subunit oligomerization and rearrangement revealed by fluorescence resonance energy transfer imaging.
Zaks-Zilberman M; Harrington AE; Ishino T; Chaiken IM
J Biol Chem; 2008 May; 283(19):13398-406. PubMed ID: 18326494
[TBL] [Abstract][Full Text] [Related]
9. The binding affinity of human pediatric respiratory syncytial virus Phosphoprotein's C-terminal tail to nucleocapsid can be improved by a rationally designed halogen-bonded system.
Xue Y; Shi X; Feng D; Wang Y
J Mol Graph Model; 2023 Jan; 118():108374. PubMed ID: 36401896
[TBL] [Abstract][Full Text] [Related]
10. Asymmetric usage of antagonist charged residues drives interleukin-5 receptor recruitment but is insufficient for receptor activation.
Ishino T; Pillalamarri U; Panarello D; Bhattacharya M; Urbina C; Horvat S; Sarkhel S; Jameson B; Chaiken I
Biochemistry; 2006 Jan; 45(4):1106-15. PubMed ID: 16430207
[TBL] [Abstract][Full Text] [Related]
11. Halogen bonds involved in binding of halogenated ligands by protein kinases.
Poznański J; Winiewska M; Czapinska H; Poznańska A; Shugar D
Acta Biochim Pol; 2016; 63(2):203-14. PubMed ID: 27104680
[TBL] [Abstract][Full Text] [Related]
12. Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis.
Gevaert P; Bachert C; Holtappels G; Novo CP; Van der Heyden J; Fransen L; Depraetere S; Walter H; van Cauwenberge P; Tavernier J
Allergy; 2003 May; 58(5):371-9. PubMed ID: 12752323
[TBL] [Abstract][Full Text] [Related]
13. Identification of regions within the third FnIII-like domain of the IL-5Ralpha involved in IL-5 interaction.
Czabotar PE; Holland J; Sanderson CJ
Cytokine; 2000 Jul; 12(7):867-73. PubMed ID: 10880230
[TBL] [Abstract][Full Text] [Related]
14. Molecular conversion of MIG6 hotspot-3 peptide from the nonbinder to a moderate binder of HER2 by rational design of an orthogonal interaction system at the HER2-peptide interface.
Zhang A; Liu P; Dou C; Liu Y; Che L
Biophys Chem; 2021 Sep; 276():106625. PubMed ID: 34077816
[TBL] [Abstract][Full Text] [Related]
15. Recruitment pharmacophore for interleukin 5 receptor alpha antagonism.
Bhattacharya M; Pillalamari U; Sarkhel S; Ishino T; Urbina C; Jameson B; Chaiken I
Biopolymers; 2007; 88(1):83-93. PubMed ID: 17041908
[TBL] [Abstract][Full Text] [Related]
16. A potent dimeric peptide antagonist of interleukin-5 that binds two interleukin-5 receptor alpha chains.
England BP; Balasubramanian P; Uings I; Bethell S; Chen MJ; Schatz PJ; Yin Q; Chen YF; Whitehorn EA; Tsavaler A; Martens CL; Barrett RW; McKinnon M
Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6862-7. PubMed ID: 10823900
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process.
Liu LY; Sedgwick JB; Bates ME; Vrtis RF; Gern JE; Kita H; Jarjour NN; Busse WW; Kelly EA
J Immunol; 2002 Dec; 169(11):6459-66. PubMed ID: 12444155
[TBL] [Abstract][Full Text] [Related]
18. Halogen bonds as orthogonal molecular interactions to hydrogen bonds.
Voth AR; Khuu P; Oishi K; Ho PS
Nat Chem; 2009 Apr; 1(1):74-9. PubMed ID: 21378804
[TBL] [Abstract][Full Text] [Related]
19. Structure analysis of the IL-5 ligand-receptor complex reveals a wrench-like architecture for IL-5Rα.
Patino E; Kotzsch A; Saremba S; Nickel J; Schmitz W; Sebald W; Mueller TD
Structure; 2011 Dec; 19(12):1864-75. PubMed ID: 22153509
[TBL] [Abstract][Full Text] [Related]
20. Rational derivation of CETP self-binding helical peptides by π-π stacking and halogen bonding: Therapeutic implication for atherosclerosis.
Zhu J; Lu M; Zhu L
Bioorg Chem; 2016 Oct; 68():259-64. PubMed ID: 27611728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
